These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34219522)

  • 1. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers.
    Segal GS; Xie SJ; Paracha SU; Grossberg GT
    J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
    Isaacson SH; Citrome L
    Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 7. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
    Pagan FL; Schulz PE; Torres-Yaghi Y; Pontone GM
    CNS Drugs; 2024 May; 38(5):333-347. PubMed ID: 38587586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
    Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
    Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease psychosis: presentation, diagnosis and management.
    Schneider RB; Iourinets J; Richard IH
    Neurodegener Dis Manag; 2017 Dec; 7(6):365-376. PubMed ID: 29160144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 17. Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.
    Dashtipour K; Gupta F; Hauser RA; Karunapuzha CA; Morgan JC
    Parkinsons Dis; 2021; 2021():2603641. PubMed ID: 33489083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease psychosis: symptoms, management, and economic burden.
    Hermanowicz N; Edwards K
    Am J Manag Care; 2015 Aug; 21(10 Suppl):s199-206. PubMed ID: 26296199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
    Daeschler D; Fugh-Berman A
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson disease psychosis: Update.
    Friedman JH
    Behav Neurol; 2013 Jan; 27(4):469-77. PubMed ID: 23242358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.